12 results about "Anti-apoptosis" patented technology

The invention relates to an agent containing zingerone, an active plant compound derived from ginger that is easy to use, non-toxic, antioxidant, and anti-apoptotic, for the treatment of diabetes-related male reproductive damage.

An apoptosis-promoting solid dispersion comprises a Bcl-2 family protein inhibiting compound of Formula A as defined herein dispersed in a solid matrix comprising (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A method for preparing such a solid dispersion comprises subjecting a compound of Formula A, a water-soluble polymeric carrier, and a surfactant to high temperature treatment to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound substantially non-crystalline form dispersed therein. The solid dispersion is suitable for oral administration to a subject in need thereof to treat a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, such as a cancer or an immune or autoimmune disease.

This invention relates to a detection kit and preparation method for enhancing the detection efficacy of autoimmune encephalitis (CBA) antibodies. The kit comprises genetically engineered 293T cells stably integrating and co-expressing the eIF2α S52A mutant and HSP70, and transiently transfected with CBA-associated antigens. The preparation method includes constructing a co-expression vector, establishing a stable transfection cell line, stress preconditioning treatment, antigen transfection, and kit assembly. A method for assessing antibody affinity maturation using this kit is also provided. By synergistically modifying detection cells at three levels—translational regulation, protein folding, and anti-apoptosis—the invention significantly increases antigen expression, reduces apoptosis, and improves detection sensitivity and specificity. Furthermore, it integrates antibody affinity assessment into CBA detection for the first time, providing auxiliary information for clinical staging.

The application belongs to the technical field of medicine, and discloses a pentacyclic triterpene derivative, a preparation method and medical application of the pentacyclic triterpene derivative, which uses alpha-hederin or oleanolic acid as raw material, and utilizes esterification reaction or amidation reaction aiming at the carboxyl of C-28 to prepare the pentacyclic triterpene derivative. The pentacyclic triterpene derivative prepared by the application has the effects of anti-inflammation, anti-oxidation and anti-apoptosis, and the synthesis method is simple, the raw material is cheap and easy to obtain, and is suitable for industrial application.

The application discloses a preparation method and application of microneedles for repairing radioactive skin damage, and adopts a physical crosslinking method to prepare the microneedles, thereby avoiding residues of organic solvents and small molecule crosslinking agents and having good biocompatibility and degradability. The microneedles can penetrate the cuticle of the skin to accurately deliver drugs to the epidermis, rapidly gel in the skin and realize programmed release of the drugs: firstly, mangiferin is released to remove active oxygen generated by radiation burst and prevent oxidative DNA damage; and then, keratin nanoparticles are continuously released to inhibit inflammatory reactions by regulating the NF-kappa B signal pathway, simultaneously play an anti-apoptosis role and up-regulate the expression of cell keratin, thereby promoting barrier reconstruction and hair follicle regeneration. The microneedle system realizes early-stage antioxidant prevention, late-stage anti-inflammatory and anti-apoptosis and regeneration-promoting phased synergistic treatment, has the effects of removing active oxygen, inhibiting inflammation, resisting cell apoptosis and promoting epidermal regeneration, and can significantly improve the repair efficiency of radioactive skin damage.

Mastocytosis is a rare and heterogeneous disorder marked by the abnormal accumulation of mast cells (MCs) in various tissues. Tyrosine kinase inhibitors have shown limited efficacy, suggesting that additional molecular mechanisms are involved. The inventors showed the unexpected expression of AXL in neoplastic mast cells from patients with various forms of mastocytosis. This is particularly noteworthy as AXL expression had never been investigated in mast cells, whether neoplastic or normal. The study demonstrated the role of AXL, particularly in cooperation with KIT D816V to drive mast cell proliferation and resistance to therapies. In an embodiment, the AXL inhibitor bemcentinib (R428) is used in combination with the TKI midostaurin (PKC 412). The AXL-L197M identified in the ASM patient is pro-proliferative, and induces resistance to death in CD34-derived mast cells and in Ba-f3. Furthermore, the results also suggest that a combination of AXL inhibitors and BCL-2 inhibitors may be appropriate for the treatment of mastocytosis. In conclusion, AXL inhibitors can be thus suitable for the treatment of mastocytosis.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

This invention relates to a drug for treating ischemia-reperfusion injury and its application. The drug activates the CCL2-chemokine receptor 2 signaling axis, triggering the downstream G protein αi2 subunit-mediated phosphatidylinositol 3-kinase / protein kinase B signaling pathway. This, in turn, synergistically regulates the antioxidant defense system driven by nuclear factor erythroid 2-related factor 2 and the B-cell lymphoma 2-mediated anti-apoptotic pathway, thereby treating the ischemia-reperfusion injury. The results of this study establish a novel therapeutic strategy for testicular ischemia-reperfusion injury based on engineered exosomes, and simultaneously reveal the previously undiscovered cytoprotective role of the CCL2 / CCR2 signaling axis in non-immune cells.

The present application relates to the technical field of medicine, discloses a kind of spinal cord organoid preparation based on trichostatin A pretreatment, including human induced pluripotent stem cell differentiation obtained human spinal cord organoid, trichostatin A and GelMA hydrogel;Wherein, the trichostatin A is used to carry out pretreatment to the human spinal cord organoid before transplantation, to activate NRF2 / HO-1 signal pathway;And its application in preparing drug for treating spinal cord injury.The application combines TSA pretreatment and hSCOs transplantation for the first time, realizes the double advantages of "drug pretreatment enhances cell therapy", clearly that TSA plays the role of antioxidation and anti-apoptosis through NRF2 / HO-1 signal pathway, significantly enhances the survival ability of hSCOs in injury microenvironment, and has good clinical transformation prospect.

Recent studies indicate that molecular hydrogen (H2) has anti-oxidative, anti-inflammatory and anti-apoptotic properties. Provided herein are compositions and methods that include hydrogen gas or a mixture of hydrogen gas and oxygen gas for ocular therapies and tissue healing. The compositions can be incorporated into a container with a quick-release seal allowing for efficient topical administration of the medicaments of the composition to tissues desired for treatment, such as the human eye.

This invention provides a method for preparing mesenchymal stem cells through 3D cell spheroid induction and hypoxia-hypothermia synergistic treatment, and its application, relating to the technical fields of regenerative medicine and cell therapy. The preparation method includes: inducing and culturing mesenchymal stem cells to obtain 3D cell spheroids; and subjecting the 3D cell spheroids to hypoxia-hypothermia treatment to obtain hypoxia-hypothermia-treated 3D cell spheroids. This invention achieves a synergistic enhancement of cell stemness, anti-apoptosis, and secretory function through 3D cell spheroid induction followed by hypoxia-hypothermia treatment. When these cells are used for pre-transplantation in SAA mice, they simultaneously achieve the triple effects of "accelerated hematopoietic reconstitution, reduced incidence of GVHD, and decreased risk of fibrosis."

The present invention provides vectors for delivery of an anti-apoptotic therapy. The vectors include a phosphoglycerate kinase (Pgk) promoter operably connected to a polynucleotide encoding an anti-apoptotic BCL2 protein (e.g., BCLXL). The vectors may be used in methods of treating conditions associated with apoptosis, including glaucoma.